890 related articles for article (PubMed ID: 12369794)
21. A combination of low doses of 17 beta-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women.
Delmas PD; Confavreux E; Garnero P; Fardellone P; de Vernejoul MC; Cormier C; Arce JC
Osteoporos Int; 2000; 11(2):177-87. PubMed ID: 10793878
[TBL] [Abstract][Full Text] [Related]
22. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women.
Eiken P; Kolthoff N; Nielsen SP
Bone; 1996 Nov; 19(5 Suppl):191S-193S. PubMed ID: 8922661
[TBL] [Abstract][Full Text] [Related]
23. Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate.
Tiraş MB; Noyan V; Yildiz A; Biberoğlu K
Climacteric; 2000 Jun; 3(2):92-101. PubMed ID: 11910657
[TBL] [Abstract][Full Text] [Related]
24. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
[TBL] [Abstract][Full Text] [Related]
25. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.
Warming L; Ravn P; Christiansen C
Maturitas; 2005 Feb; 50(2):78-85. PubMed ID: 15653003
[TBL] [Abstract][Full Text] [Related]
26. Peripheral quantitative computed tomography (pQCT) is useful for monitoring bone mineral density of the patients who receive hormone replacement therapy.
Sawada K; Morishige K; Ohmichi M; Nishio Y; Yamamoto T; Hayakawa J; Mabuchi S; Isobe A; Sasaki H; Sakata M; Tasaka K; Murata Y
Maturitas; 2007 Apr; 56(4):343-9. PubMed ID: 17010541
[TBL] [Abstract][Full Text] [Related]
27. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.
Ste-Marie LG; Schwartz SL; Hossain A; Desaiah D; Gaich GA
J Bone Miner Res; 2006 Feb; 21(2):283-91. PubMed ID: 16418784
[TBL] [Abstract][Full Text] [Related]
28. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial.
Arrenbrecht S; Boermans AJ
Osteoporos Int; 2002; 13(2):176-83. PubMed ID: 11908492
[TBL] [Abstract][Full Text] [Related]
29. A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group.
Delmas PD; Pornel B; Felsenberg D; Garnero P; Hardy P; Pilate C; Dain MP
Bone; 1999 May; 24(5):517-23. PubMed ID: 10321913
[TBL] [Abstract][Full Text] [Related]
30. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
[TBL] [Abstract][Full Text] [Related]
31. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients.
Kushida K; Takahashi M; Kawana K; Inoue T
J Clin Endocrinol Metab; 1995 Aug; 80(8):2447-50. PubMed ID: 7629240
[TBL] [Abstract][Full Text] [Related]
32. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial.
Prestwood KM; Kenny AM; Kleppinger A; Kulldorff M
JAMA; 2003 Aug; 290(8):1042-8. PubMed ID: 12941676
[TBL] [Abstract][Full Text] [Related]
33. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
Gallagher JC; Fowler SE; Detter JR; Sherman SS
J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
[TBL] [Abstract][Full Text] [Related]
34. The effect of soy isoflavone on bone mineral density in postmenopausal Taiwanese women with bone loss: a 2-year randomized double-blind placebo-controlled study.
Tai TY; Tsai KS; Tu ST; Wu JS; Chang CI; Chen CL; Shaw NS; Peng HY; Wang SY; Wu CH
Osteoporos Int; 2012 May; 23(5):1571-80. PubMed ID: 21901480
[TBL] [Abstract][Full Text] [Related]
35. Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study.
Nielsen TF; Ravn P; Bagger YZ; Warming L; Christiansen C
Osteoporos Int; 2004 Feb; 15(2):168-74. PubMed ID: 14647880
[TBL] [Abstract][Full Text] [Related]
36. Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women.
Rubinacci A; Peruzzi E; Modena AB; Zanardi E; Andrei B; De Leo V; Pansini FS; Quebe-Fehling E; de Palacios PI
Menopause; 2003; 10(3):241-9. PubMed ID: 12792297
[TBL] [Abstract][Full Text] [Related]
37. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
[TBL] [Abstract][Full Text] [Related]
38. The effect of 17beta-estradiol at doses of 0.5, 1 and 2 mg compared with placebo on early postmenopausal bone loss in hysterectomized women.
Giske LE; Hall G; Rud T; Landgren BM
Osteoporos Int; 2002; 13(4):309-16. PubMed ID: 12030546
[TBL] [Abstract][Full Text] [Related]
39. The metabolic and bone density effects of continuous combined 17-beta estradiol and noresthisterone acetate treatments in Thai postmenopausal women: a double-blind placebo-controlled trial.
Bunyavejchevin S; Limpaphayom KK
J Med Assoc Thai; 2001 Jan; 84(1):45-53. PubMed ID: 11281499
[TBL] [Abstract][Full Text] [Related]
40. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women.
Weinstein RS; Parfitt AM; Marcus R; Greenwald M; Crans G; Muchmore DB
Osteoporos Int; 2003 Oct; 14(10):814-22. PubMed ID: 14610642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
